Endocrine Comorbidities in Fibromyalgia
Authors' conclusion
This is among the largest datasets to date to systematically examine a comprehensive spectrum of endocrine comorbidities in FM. Our findings suggest that FM and endocrine disorders may share overlapping pathophysiological mechanisms. Future studies should clarify causal pathways and assess the clinical utility of routine endocrine screening in FM patients.
Study context
- Population
- Adults with fibromyalgia (FM) and age- and sex-matched controls, Leumit Health Services, Israel; endocrine disorders identified via ICD-9 codesmatched case-control
- Participants
- 9,232 vs 46,160
- Comparison
- FM patients vs matched controls
- FMn = 9,232
- Controlsn = 46,160reference
- Outcome
- Prevalence of endocrine comorbidities
Methodological detailsmatched by age and sex, multivariable logistic regression adjusting for age, sex and BMI
- Matched by age and sex
- Multivariable logistic regression adjusting for age, sex and BMI
Main finding
As reported in the abstract
Endocrine comorbidities
- Significantly higher prevalence of endocrine comorbidities in FM vs controls
Observational data: associations, not effects.
Further findings
Hashimoto's thyroiditis
OR 1.38 · P < 0.001
GD
OR 1.38 · P < 0.001
T1D
- Significantly associated: OR
- OR = 3.64, p < 0.001
T2D
- Significantly associated: OR
- OR = 1.34, p < 0.001
CS
- Significantly associated: OR
- OR = 5.01, p < 0.001
Prolactinoma
- Significantly associated: OR
- OR = 1.81, p = 0.014
Osteoporosis
- Significantly associated: OR
- OR = 1.80, p < 0.001
Vitamin D deficiency
- Significantly associated: OR
- OR = 1.53, p < 0.001
Less common conditions (e.g., thyroiditis subtypes, thyroid malignancy)
- Appeared more frequent among FM patients; effect sizes varied and some associations did not reach robust significance
Original publication
Endocrine Comorbidities in Fibromyalgia. Clin Endocrinol (Oxf). Published 25 November 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →